SecBot SecBot
Biotech Drug Report Generated Oct 24, 2026

QDENGA

RDY·DR REDDYS LABORATORIES LTD
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved by CDSCO (India) in July 2026; anticipated to become available in India's private market in the first half of 2027.
Why 3/10
The next catalyst is the commercial launch of QDENGA in India's private market, anticipated in H1 2027. However, Dr. Reddy's is only the Indian distributor for Takeda's already-approved vaccine, there is no binary regulatory catalyst ahead. The deal terms were not disclosed, and for a ~$11B diversified pharma company, this is a small portfolio addition, not a company-defining event.
⚠ Few sources Few sources were found for this drug. Treat the rating as low-confidence and verify against the cited sources.
Actionable Insight NEUTRAL

Watch for the commercial launch of QDENGA in India's private market in H1 2027, which will be Dr. Reddy's first foray into vaccine distribution. The financial terms were not disclosed, so the revenue contribution is unclear, this is a distribution deal, not a development deal, and is unlikely to be a needle-mover for a ~$11B market cap company. Monitor quarterly results for any disclosed revenue from the partnership.

Price Chart

Loading chart...

Executive Summary

QDENGA (TAK-003) is a live-attenuated tetravalent dengue vaccine developed and manufactured by Takeda Pharmaceutical Co. (NYSE: TAK). It is already approved in multiple global markets including the EU, UK, Brazil, and several Asian countries. Dr. Reddy's Laboratories (NYSE: RDY) entered into an exclusive distribution and marketing agreement with Takeda for QDENGA in India's private market. The vaccine was approved by India's CDSCO in July 2026 and is expected to launch in H1 2027. For Dr. Reddy's, this is a commercial distribution deal for an already-approved product, not a development-stage binary. The financial terms were not disclosed, and for a diversified ~$11B pharmaceutical company, this represents a modest portfolio expansion rather than a company-defining catalyst.

How It Works

QDENGA is a live-attenuated tetravalent dengue vaccine, meaning it contains weakened versions of all four dengue virus serotypes. It trains the immune system to recognize and fight the dengue virus without causing the disease itself. It is given as a two-dose subcutaneous injection three months apart.

Trial Status

QDENGA is already approved in multiple global markets. Takeda completed pivotal Phase 3 trials (TIDES) demonstrating efficacy against all four dengue serotypes. India's CDSCO approved the vaccine in July 2026. Dr. Reddy's will distribute it in India's private market starting H1 2027.

The Two-Sided Case

▲ Bull Case5
QDENGA is an approved, commercially established vaccine in multiple global markets (EU, UK, Brazil, Argentina, Indonesia, Thailand), Dr. Reddy's is not taking development risk.
India has a high dengue burden, creating a large addressable market for the vaccine in the private sector.
Dr. Reddy's strong India commercial infrastructure (17% YoY growth in India segment in Q2FY27) provides a ready distribution channel.
The vaccine was approved by CDSCO in July 2026 and is expected to launch in H1 2027, providing a near-term commercial catalyst.
Diversification into vaccines expands Dr. Reddy's portfolio beyond its core small-molecule generics business.
▼ Bear Case5
Dr. Reddy's is only a distributor, not the developer, margins on distribution deals are typically thin and the financial terms were not disclosed, suggesting limited materiality.
India's private vaccine market is price-sensitive; dengue vaccination is not part of the national immunization program, limiting volume potential.
QDENGA faces potential competition from other dengue vaccines (e.g., Sanofi's Dengvaxia) and any future entrants.
Dr. Reddy's core business (generics, especially lenalidomide in North America) is under structural pressure, QDENGA distribution is too small to offset that headwind.
No upfront or milestone payments were disclosed, implying the deal may not have required significant investment but also may not generate meaningful returns.

Upcoming Catalysts

  • Commercial launch of QDENGA in India's private market (anticipated H1 2027)
  • Potential expansion into India's public immunization programs (speculative, no timeline)
  • Quarterly earnings disclosures of any QDENGA-related revenue

Source Filing

The SecBot filing or press-release report that triggered this drug report:

DR REDDYS LABORATORIES LTD 6-K RDY ·Originating report

Sources · 1

Hover a chip for the title
1 sec.gov